We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

40 hedge funds and large institutions have $677M invested in Phathom Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

88.91% more ownership

Funds ownership: 0% → 88.91% (+89%)

Holders
40
Holders Change
+40
Holders Change %
–
% of All Funds
0.79%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.1%
New
40
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
FM
Frazier Management
Washington
+$183M
2
RCM
RA Capital Management
Massachusetts
+$91.7M
3
Invesco
Invesco
Georgia
+$52.8M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$36.9M
5
A
Abingworth
United Kingdom
+$30.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$227M +$183M +7,284,269 New
RCM
2
RA Capital Management
Massachusetts
$114M +$91.7M +3,646,808 New
Invesco
3
Invesco
Georgia
$65.5M +$52.8M +2,102,303 New
MVM
4
Medicxi Ventures Management
Jersey
$64.4M +$52M +2,067,861 New
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$43.6M +$36.9M +1,467,462 New
A
6
Abingworth
United Kingdom
$37.4M +$30.2M +1,203,135 New
BI
7
BVF Inc
California
$24.5M +$19.8M +785,851 New
BlackRock
8
BlackRock
New York
$20M +$16.1M +640,715 New
Ensign Peak Advisors
9
Ensign Peak Advisors
Utah
$19.2M +$15.5M +616,857 New
EAM
10
Eventide Asset Management
Massachusetts
$14M +$11.3M +450,000 New
GA
11
Greenspring Associates
Maryland
$11.2M +$9.07M +360,939 New
Norges Bank
12
Norges Bank
Norway
$9.88M +$7.97M +317,300 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$6.42M +$5.18M +205,995 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.78M +$3.86M +153,434 New
State Street
15
State Street
Massachusetts
$3.9M +$3.15M +125,243 New
Northern Trust
16
Northern Trust
Illinois
$3.56M +$2.88M +114,426 New
Charles Schwab
17
Charles Schwab
California
$2.11M +$1.7M +67,787 New
N
18
Nuveen
North Carolina
$1.1M +$888K +35,345 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$772K +$623K +24,794 New
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
$721K +$582K +23,141 New
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$512K +$413K +16,437 New
Morgan Stanley
22
Morgan Stanley
New York
$450K +$363K +14,441 New
UBS Group
23
UBS Group
Switzerland
$439K +$354K +14,099 New
AC
24
Athanor Capital
New York
$416K +$336K +13,373 New
New York State Common Retirement Fund
25
New York State Common Retirement Fund
New York
$302K +$244K +9,700 New
1
2

PHAT Hedge Fund Activity: Q4 2019 in Review

40 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2019, worth a combined $677M.

Buyers outnumbered sellers: 40 funds opened new PHAT positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Frazier Management, opening a new position worth an estimated $183M.

  • 40 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2019, up from 0 in Q3 2019.
  • Funds reported $677M of Phathom Pharmaceuticals stock for Q4 2019.
  • 40 funds opened new Phathom Pharmaceuticals positions in Q4 2019 and 0 closed out, a net change of +40 holders.
  • The largest Phathom Pharmaceuticals buyer in Q4 2019 was Frazier Management, an estimated $183M added.

Based on aggregated 13F filings for Q4 2019.